Welcome to our dedicated page for Walgreen Boots SEC filings (Ticker: WBA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page aggregates U.S. Securities and Exchange Commission filings for Walgreens Boots Alliance, Inc. (historically Nasdaq: WBA) and related securities, with AI-powered tools to help interpret the regulatory record. These documents trace the company’s transition from a publicly traded integrated healthcare, pharmacy and retail group to a privately held subsidiary of Blazing Star Parent, LLC, an affiliate of Sycamore Partners.
Among the most significant filings is the Form 8-K dated August 28, 2025, which reports the completion of the merger of Blazing Star Merger Sub, Inc. with and into Walgreens Boots Alliance, Inc. This filing explains that each share of company common stock was converted into the right to receive cash consideration and a divested asset proceed right, and that the company would become a wholly owned subsidiary of Blazing Star Parent, LLC. The same Form 8-K also describes the termination of certain credit facilities and the notice to The Nasdaq Stock Market LLC that WBA common stock and specified notes would be removed from listing.
A related Form 25, filed on August 28, 2025, documents the removal of Walgreens Boots Alliance, Inc. common stock and certain notes from listing and registration on Nasdaq. Subsequently, a Form 15 filed on September 8, 2025 certifies the termination of registration of the company’s common stock and various series of notes under Section 12(g) of the Securities Exchange Act of 1934 and the suspension of the duty to file reports under Sections 13 and 15(d). Together, these filings confirm WBA’s delisting and deregistration following the merger.
Earlier Form 8-K filings provide additional context on the transaction and corporate actions. These include disclosures about the Agreement and Plan of Merger with Blazing Star Parent, LLC and Blazing Star Merger Sub, Inc., the special meeting of stockholders held to vote on the merger agreement, the temporary suspension of trading under employee benefit plans in connection with the transaction, and supplemental proxy statement disclosures addressing shareholder litigation and demand letters related to the merger. Another Form 8-K furnishes a press release announcing financial results for the fiscal quarter ended May 31, 2025.
Debt-related filings and referenced documents, including press releases by Blazing Star Merger Sub, Inc., describe tender offers and consent solicitations for multiple series of Walgreens Boots Alliance, Inc. and Walgreen Co. notes, along with pricing terms, early tender results and extensions of expiration times. These materials are relevant for understanding how the company and its acquirer managed outstanding debt securities around the time of the merger.
On this SEC filings page, users can review these historical documents in one place. AI-powered summaries highlight key terms from complex forms such as Form 8-K, Form 25 and Form 15, explain the implications of delisting and deregistration, and clarify how equity and debt holders were affected by the merger. Real-time connections to the EDGAR system ensure that filings related to WBA’s historical record are captured, while AI tools help interpret legal and financial language so that readers can more easily understand corporate actions, capital structure changes and the company’s transition from public to private ownership.
Walgreens Boots Alliance, Inc. (WBA) appears in a Form 25 notification filed with the SEC to remove a class of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing identifies the issuer's principal office at 200 Wilmot Road, Deerfield, Delaware, and notes that Nasdaq certifies it has complied with the rules under 17 CFR 240.12d2-2(b) and that the issuer has complied with 17 CFR 240.12d-2(c) for voluntary withdrawal procedures. The document does not state which specific class of securities is being removed, the effective date, or the reason for removal.
Robert Luther Huffines, a director of Walgreens Boots Alliance, Inc. (WBA), received an annual phantom stock grant reported on Form 4 with a transaction date of 08/13/2025. The grant comprised 16,820.86 phantom stock units with an attributed price of $11.89 per underlying share; each phantom unit is the economic equivalent of one share of common stock. The units are to be settled following termination of service under the company’s 2021 Omnibus Incentive Plan. After this grant, Mr. Huffines’ total phantom stock units beneficially owned are 46,813.12, which includes units issued in lieu of dividends.
Walgreens Boots Alliance director Ginger L. Graham was granted 16,820.86 phantom stock units on 08/13/2025 as non-employee director compensation under the company's 2021 Omnibus Incentive Plan. Each phantom unit is the economic equivalent of one share of common stock and will be settled following termination of service in accordance with the Plan. The reported per-unit value for the grant is $11.89, and the filing shows 112,782.56 phantom stock units beneficially owned following the transaction, which includes units issued in lieu of dividends.
The Form 4 was signed on behalf of Ms. Graham by an attorney-in-fact, Paul Ingram, on 08/15/2025. The filing is a routine disclosure of director compensation and deferred equity-like awards under the issuer’s director pay framework.
Janice M. Babiak, a director of Walgreens Boots Alliance, Inc. (WBA), received an annual grant of phantom stock units as director compensation. The Form 4 reports a grant dated 08/13/2025 of 16,820.86 phantom stock units, each economically equivalent to one share of common stock and priced at $11.89 for reporting purposes. After this award, Ms. Babiak beneficially owns 99,494.27 phantom stock units, which include units issued in lieu of dividends. The units are payable following termination of director service under the company’s 2021 Omnibus Incentive Plan. The Form 4 is signed on behalf of Ms. Babiak by an attorney-in-fact.
Walgreens Boots Alliance director Bryan C. Hanson received an annual non-employee director share grant of 16,820 common shares on 08/13/2025 as compensation for prior-year services under the company's 2021 Omnibus Incentive Plan. The grant carried a reported price of $0, reflecting compensation rather than a cash purchase, and increased Mr. Hanson’s total beneficial ownership to 47,655 shares. The Form 4 reports the transaction type as an award for director compensation and identifies the reporting person as a company director.
Valerie B. Jarrett, a director of Walgreens Boots Alliance (WBA), received an annual grant of phantom stock units as director compensation. On 08/13/2025 she was granted 16,820.86 phantom stock units, each economically equivalent to one share of WBA common stock, at a reported per-unit price of $11.89. The units are to be settled following termination of her service under the companys 2021 Omnibus Incentive Plan and include units issued in lieu of dividends. After the grant Jarrett beneficially owned 86,025.29 phantom stock units. The Form 4 was signed on 08/15/2025 by an attorney-in-fact.
Inderpal S. Bhandari, a director of Walgreens Boots Alliance, Inc. (WBA), received an annual phantom stock grant on 08/13/2025 as non-employee director compensation under the company's 2021 Omnibus Incentive Plan. The report shows 16,820.86 phantom stock units were acquired at an economic price of $11.89 per unit, and the reporting person now beneficially owns 49,779.04 phantom stock units. Each phantom stock unit is the economic equivalent of one share and these units are to be settled following termination of director service according to the Plan. The grant includes units issued in lieu of dividends on outstanding phantom stock units.
John Anthony Lederer, a director of Walgreens Boots Alliance, received an annual grant of 16,820.86 phantom stock units dated 08/13/2025 as non-employee director compensation under the company's 2021 Omnibus Incentive Plan. Each unit is economically equivalent to one share of common stock and the grant is paid in arrears for prior-year services. The phantom units vest to be settled following termination of director service and include additional units issued in lieu of dividends. The filing reports 125,173.95 common stock equivalents beneficially owned after the grant. The Form 4 was signed on behalf of Mr. Lederer by an attorney-in-fact on 08/15/2025.
Thomas E. Polen Jr., a director of Walgreens Boots Alliance, acquired equity compensation on 08/13/2025. The filing shows an annual non-employee director stock award of 11,774 common shares issued under the company's 2021 Omnibus Incentive Plan for services rendered the prior year, and an annual phantom stock grant of 5,046.26 units, each unit economically equivalent to one share. Following these grants, Mr. Polen beneficially owned 28,269 common shares and 12,356.58 shares represented by phantom units (including units issued in lieu of dividends). The phantom units are to be settled following termination of director service per the Plan.
William H. Shrank, a director of Walgreens Boots Alliance, Inc. (WBA), received an annual grant of 16,820.86 phantom stock units on 08/13/2025 as non-employee director compensation under the company's 2021 Omnibus Incentive Plan. Each phantom stock unit is the economic equivalent of one share of WBA common stock and the reported per-unit valuation is $11.89. The units are classified as derivative securities and are to be settled following termination of Shrank's service as a director in accordance with the Plan. The Form 4 was signed on 08/15/2025 by William Shrank via attorney-in-fact Cherita Thomas.